Jump to content

Auntie-D

Members
  • Posts

    997
  • Joined

  • Last visited

  • Days Won

    32
  • Country

    United Kingdom

Posts posted by Auntie-D

  1. My novice interpretation of this article:

    Their test was to see if they could identify parasites in the buffy coat that they didn't see in a thick film, in patients they thought it should be possible due to previous thick film identifications.

    And yes, they did in ~27% of cases.

    Their recommendation was for add'l studies due to low sample size but that it might be a useful tool to consider to prevent false negatives.

     

    The initial slides were positive and the susequent slides were negative. What I was trying to say was neither method should be used to determine efficacy of treatment due to the latent phase of treatment. And it certainly shouldn't be used as a primary diagnostic tool.

  2. It state

     

    Apparently the use of a buffy coat smear to detect malaria came from a 2011 study that was published in the Asian Pacific Journal of Tropical Biomedicine.   I does state however that a larger and more complete study should be performed before implementing this into common practice. 

    Here is the link if you’re interested.  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609286/

     

    It states that there are 36 examined that have been detected by conventional thick films already and the patient is already undergoing treatment. The buffy coat ones are taken after treatment - so assumedly only to detect whether the treatment is complete?

     

    I think it is risky to use any form of films to determine completeness of the treatment as it may be that the malaria has gone into hepatic cells and is no longer circulating.

     

    It definitely shouldn't be used as a primary diagnostic tool IMO.

  3. I did one on the importance of recognising delta check failures in other departments and the implications in transfusion - and why they should let us know. Overtransfusion and the risk of TOCO in dilutional samples and the risk of ABO incompatibility if WBIT.

  4. We use MI and FI and the mother's forname. Once the baby has been given a name we change the record and put the mum's name, DOB and hospital number in the patient notes file for the baby so they can always be tied back.

     

    My baby would be FI of Dee, AUNTIE, 5/8/15

  5. We had a patient just last week with a known anti-D showing no reaction at all in the antibody screen on this occasion - she was panelled with enzyme and showed 3+ reaction. I didn't even know this could happen! I though anti-D and anti-K stayed detectable for life...

     

    Could it be that she was like this lady and the new pregancy has elicited an immune response bringing titres to a detectable level again?

  6.  I have seen places that freeze preops and save for up to a month. It all depends on your Medical Director's comfort level and the pressure exerted by the Medical staff.

     Somewhere I used to work did this - aliquoted off the plasma and froze it. I was never comfortable with it personally due to the risk of someone aliquotting more than one sample at a time when rushing (ie prelabelling tubes). I shouldn't happen but it did...

  7. No, that is most definitely NOT true Auntie-D.

     

    Many cold-reacting anti-M's are IgG in nature, and even if you can detect an anti-M in a tube technique, it is not necessarily clinically significant unless it can be detected at strictly 37oC (see Daniels G, Poole J, de Silva M, Callaghan T, MacLennan T, Smith N.  The clinical significance of blood group antibodies.  Transfusion Medicine 2002; 12: 287-295).

     

    But if it is detectable in gel, and causes HDN in that particular patient, you can't just discount it because it doesn't react in tube.

     

    In vivo always wins over in vitro of course

  8. We have seen immune, IgG anti-M formation as well, most recently 2 days ago, but the issue in this post is that the antibody is undetectable in tube.  Were it positive in tube as well, it would have to be considered clinically significant, but since it is only detectable in solid phase (or gel, in my case) I don't believe it can be considered significant.

     

    Surely it is considered clinically significant if it reacts in the patient, regardless of whether or not it reacts in tube ;)

×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.